The ZA001 F1F3 ointment, independently developed by Zhong'ao Biopharm, a biopharmaceutical technology in the Bay Area Medicine Valley in Zhongshan's Torch Development Zone, obtained clinical trial approval from the National Medical Products Administration on February 19. It is expected to reshape the global treatment landscape of HPV-related diseases.

The company is also targeting the 6-billion-US dollars market for skin precancerous lesions and is set to initiate clinical trials in Australia.

Akeso, another leading enterprise in the Bay Area Medicine Valley, has also started the new year with a series of successes.

In mid-February, Akeso's Investigational New Drug application for AK139, a bispecific antibody targeting IL-4Rα and ST2, was accepted by the China National Medical Products Administration, following the acceptance of the New Drug Application for the company's self-developed IL-17-targeting monoclonal antibody gumokimab on January 27.

A complete ecosystem, from original innovation to industrial transformation, has been developed within the Bay Area Medicine Valley. It now boasts 94 pharmaceutical pipelines in research, nearly 30 Class-I new drugs under research and 6 Class-I new drugs launched in the market, covering fields such as oncology, immunology and infectious diseases.